ROCKVILLE, Md., June 18 /PRNewswire-FirstCall/ — Novavax,
Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced
today that Dr. Rahul Singhvi,
President and Chief Executive Officer, will be presenting at the
Phacilitate Vaccine Forum Barcelona 2010 conference on June 21 and June 22,
2010 at The Fira Palace, Barcelona, Spain. Dr. Singhvi is
participating in the roundtable discussion, ‘Getting ready for
the next influenza pandemic: How are recent experiences informing
ongoing preparedness strategies?’ and will also be
speaking on the Case Study: ‘Update on novel vaccine
technologies and platforms that have been developed for the
influenza market.’
About Novavax
Novavax, Inc. is a clinical-stage biopharmaceutical company
creating novel vaccines to address a broad range of infectious
diseases worldwide, including H1N1, using advanced proprietary
virus-like-particle (VLP) technology. The company produces
potent VLP-based, recombinant vaccines utilizing new and efficient
manufacturing approaches. Novavax is committed to using its VLP
technology to create country-specific vaccine solutions. In
2009, Novavax launched a joint venture with Cadila Pharmaceuticals,
named CPL Biologicals, to develop and manufacture vaccines,
biological therapeutics and diagnostics in India. Additional information
about Novavax is available on the company’s website:
SOURCE